TickerFacts.

BridgeBio Oncology Therapeutics, Inc. (BBOT): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$113.89M
Year ended 2025-12-31
2024-12-31: -$55.03M2025-12-31: -$113.89M-$113.89M
2024-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$113.89Mn/m2026-03-05, From 2025-01-01
2024-12-31-$55.03Mn/a2026-03-05, From 2024-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
BridgeBio Oncology Therapeutics, Inc. (BBOT)2025-12-31-$113.89Mn/m
Biohaven Ltd. (BHVN)2025-12-31-$609.44Mn/m
BGM Group Ltd. (BGM)2025-09-30-$2.37Mn/m
Arcutis Biotherapeutics, Inc. (ARQT)2025-12-31-$5.62Mn/m
Bicara Therapeutics Inc. (BCAX)2025-12-31-$106.83Mn/m
MoonLake Immunotherapeutics (MLTX)2025-12-31-$196.01Mn/m
Enliven Therapeutics, Inc. (ELVN)2025-12-31-$70.30Mn/m
MapLight Therapeutics, Inc. (MPLT)2025-12-31-$138.14Mn/m
Rhythm Pharmaceuticals, Inc. (RYTM)2025-12-31-$115.67Mn/m

Compare BBOT, BHVN, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗